Investigation of the Effect of Date Consumption on Hedonic Hunger and Appetite in Adult Individuals With Type 2 Diabetes
NCT06826235
Summary
The aim of this study was to investigate the effects of date consumption on hedonic hunger and appetite hormones in individuals diagnosed with type 2 diabetes.The main questions it aims to answer are: * Does date consumption reduce hedonic hunger in individuals with type 2 diabetes? * Does persimmon consumption change Ghrelin, GLP-1 and GIP concentrations in individuals with Type 2 diabetes? * Does persimmon consumption reduce HOMA-IR and HbA1c values in individuals with Type 2 diabetes? * Does consumption of persimmon reduce LDL cholesterol, total cholesterol and triglyceride concentrations in individuals with type 2 diabetes? To see the effects of date consumption on hedonic hunger and appetite hormones, the researchers will compare individuals with type 2 diabetes who consume 3 dates daily with individuals with type 2 diabetes who do not. Participants: * Individuals in the intervention group will consume 3 (25 g) Baghdad dates (15 g CHO) daily as part of the breakfast meal, while individuals in the control group will not consume dates. * Three interviews will be conducted with patients. * A record of blood findings and questionnaires will be kept during these interviews.
Eligibility
Inclusion Criteria: * Individuals diagnosed with Type 2 diabetes aged 19-50 years (excluding menopausal women), * Individuals with BMI between 25-35 kg/m2, * Individuals with a Nutritional Strength Scale score of 2.5 and above, * Individuals who agreed not to start taking new dietary supplements or alternative therapies during the study period, * Individuals who agree not to change their current physical activity level and diet. Exclusion Criteria: * Individuals who do not approve the volunteer consent form, * Individuals with a Nutritional Strength Scale score below 2.5, * Pregnant or breastfeeding women (or women planning to become pregnant within 3 months) * Individuals with dietary energy \<800 kcal/day and \>4000 kcal/day, * Individuals with pre-diabetes, type 1 diabetes and gestational diabetes, * Individuals with HbA1c \>10 * Individuals taking antibiotics or hormone replacement therapy History of malignancy (except non-melanoma skin cancer). * Individuals with regular consumption of dates before inclusion in the study, * Individuals diagnosed with Type 2 diabetes using insulin and oral antidiabetic drugs with thiazolidinedione active substance, * Individuals with a history of diabetic ketoacidosis, diabetic coma or precoma within 6 months prior to the date of admission; serious infections, surgery, serious trauma requiring insulin treatment, haemodialysis treatment (including peritoneal haemodialysis), serious liver injury and serious vascular complications (stroke, myocardial infarction and heart failure) requiring hospitalisation, * Individuals taking pharmacological agents that have effects on appetite such as psychotropics, antiepileptics, antidepressants, antipsychotics and/or steroids, * Individuals diagnosed with eating disorders and/or psychological disorders, * Individuals with physical illnesses that affect eating behaviour or appetite, such as uncontrolled hyperthyroidism or hypothyroidism, Cushing's disease, acromegaly, adrenal insufficiency, chronic renal failure (stage 4 or 5), tuberculosis, human immunodeficiency virus (HIV) infection.
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06826235